Author: Daniel B Larremore; Bailey K Fosdick; Kate M Bubar; Sam Zhang; Stephen M Kissler; C. Jessica E. Metcalf; Caroline Buckee; Yonatan Grad
Title: Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys Document date: 2020_4_20
ID: c4cs14ja_3
Snippet: Serological testing is a critical component of the response to COVID-19 as well as to future epidemics. Assessment of population seropositivity, a measure of the prevalence of individuals who have been infected in the past and developed antibodies to the virus, can address gaps in knowledge of the cumulative disease incidence. This is particularly important given inadequate viral diagnostic testing and incomplete understanding of the rates of mil.....
Document: Serological testing is a critical component of the response to COVID-19 as well as to future epidemics. Assessment of population seropositivity, a measure of the prevalence of individuals who have been infected in the past and developed antibodies to the virus, can address gaps in knowledge of the cumulative disease incidence. This is particularly important given inadequate viral diagnostic testing and incomplete understanding of the rates of mild and asymptomatic infections (1) . In this context, serological surveillance has the potential to provide information about the true number of infections, allowing for robust estimates of case and infection fatality rates and for the parameterization of epidemiological models to evaluate the possible impacts of specific interventions and thus guide public health decision-making.
Search related documents:
Co phrase search for related documents- asymptomatic mild infection and public health decision making: 1
- asymptomatic mild infection and serological testing: 1, 2, 3
- case infection fatality rate and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- critical component and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- critical component and response critical component: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- cumulative disease incidence and public health: 1, 2, 3, 4, 5
- cumulative disease incidence and public health decision making: 1
- decision making and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- decision making and public health decision making: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- decision making and public health decision making guide: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- decision making and response critical component: 1
- decision making and robust estimate: 1, 2
- decision making and serological surveillance: 1
- develop past and public health: 1, 2, 3
- diagnostic testing and public health decision making: 1, 2, 3, 4, 5, 6, 7, 8
- diagnostic testing and public health decision making guide: 1
- diagnostic testing and response critical component: 1
- diagnostic testing and robust estimate: 1
- diagnostic testing and serological surveillance: 1
Co phrase search for related documents, hyperlinks ordered by date